# US 2021/0268081 A9 · Targeted expansion of qa-1-peptide-specific regulatory cd8 t cells to ameliorate arthritis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0268081 A9
- Document ID: US20210268081A9
- Status: Published application
- Kind: A9
- Application number: 16/719,814
- Filed: 2019-12-18
- Published: 2021-09-02
- Earliest claimed: 2012-09-28
- Assignees: Dana-Farber Cancer Institute, Inc.
- Applicants: Dana-Farber Cancer Institute, Inc.
- Inventors: Harvey Cantor; Hye-Jung Kim; Jianmei Wu Leavenworth
- Web page: https://patentgrep.com/patent/US20210268081A9

## CPC

- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/19: Dendritic cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/4262: {Heat shock proteins}
- C07K 14/47: from mammals
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C12N 5/0636: {T lymphocytes}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/58: {raising an immune response against a target which is not the antigen used for immunisation}
- C12N 2501/2315: Interleukin-15 (IL-15)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Nanoparticles to treat autoimmune diseases and HIV infection are provided. The nanoparticles comprise a biocompatible polymer and a complex, wherein the complex is a major histocompatibility complex (MHC) class I antigen E (HLA-E) linked to a peptide, and wherein the HLA-E-peptide complex is linked to the surface of the nanoparticle. The present invention also relates to methods for treating autoimmune diseases and HIV infection.

## Claims

### Claim at position 1

1-11. (canceled)

### Claim 12

A method for treating an autoimmune disease comprising:
administering to a subject in need of such treatment a nanoparticle comprising a biocompatible polymer and a complex, in an amount effective to ameliorate a symptom of the autoimmune disease,
wherein the complex is a major histocompatibility complex (MHC) class 1 antigen E (HLA-E) linked to a peptide, and
wherein the HLA-E peptide complex is linked to the surface of the nanoparticle.

### Claim 13 (depends on 12)

The method of claim 12, wherein the autoimmune disease is selected from the group consisting of systemic lupus erythematosus, chronic graft versus host disease, rheumatoid arthritis, insulin-dependent diabetes mellitus, multiple sclerosis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Graves disease, Crohn's disease, Waldenstrom's macroglobulinemia, hyperviscosity syndrome, monoclonal gammopathy of undetermined origin, POEMS syndrome, myeloma, macroglobulinemia, and cold agglutinin disease.

### Claim at position 4

14-32. (canceled)

### Claim 33 (depends on 12)

The method of claim 12, wherein at least 4 units, at least 5, at least 6, at least 7, at least 8, at least 9 or at least 10 units of the HLA-E-peptide complex are linked together to form a moiety and the moiety is linked to the surface of the nanoparticle.

### Claim 34 (depends on 12)

The method of claim 12, wherein the HLA-E-peptide complex comprises biotin, and the complexes are linked together through biotin-avidin interaction to form the moiety.

### Claim 35 (depends on 12)

The method of claim 12, wherein the peptide is selected from the group consisting of Hsp60p216, B7sp and FL9.

### Claim 36 (depends on 33)

The method of claim 33, wherein the HLA-E-peptide complex or the moiety is linked to the surface of the nanoparticle via PEGylation.

### Claim 37 (depends on 12)

The method of claim 12, wherein the peptide is linked to the HLA-E via a flexible linker.

### Claim 38 (depends on 37)

The method of claim 37, wherein the flexible linker is a Gly-Ser linker.

### Claim 39 (depends on 38)

The method of claim 38, wherein the Gly-Ser linker is (Gly4Ser)n or (Gly3Ser)n, and n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

### Claim 40 (depends on 12)

The method of claim 12, wherein the heavy chain and light chain (β-2 microglobulin) of the HLA-E are linked via a flexible linker.

### Claim 41 (depends on 40)

The method of claim 40, wherein the flexible linker is a Gly-Ser linker.

### Claim 42 (depends on 41)

The method of claim 41, wherein the Gly-Ser linker is (Gly4Ser)n or (Gly3Ser)n, and n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

### Claim 43 (depends on 12)

The method of claim 12, wherein the peptide is linked to the HLA-E via a first flexible linker, and the heavy chain and light chain (β-2 microglobulin) of the HLA-E are linked via a second flexible linker, wherein the first flexible linker is (Gly4Ser)3 and the second flexible linker is (Gly4Ser)4.

### Claim 44 (depends on 12)

The method of claim 12, wherein the polymer is selected from the group consisting of poly(lactic-co-glycolic acid) (PLGA), poly(ethylene glycol) (PEG), chitosan, and chitosan-PEG.

### Claim 45 (depends on 12)

The method of claim 12, wherein a low releasing dose of IL-15 is incorporated into the nanoparticle.

### Claim 46 (depends on 12)

The method of claim 12, wherein the peptide is Hsp60p216 and the polymer is poly(ethylene glycol) (PEG).
